US4364401012 - Common Stock
HOLOGIC INC
NASDAQ:HOLX (5/17/2024, 7:04:21 PM)
After market: 75.02 0 (0%)75.02
+0.07 (+0.09%)
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. The company is headquartered in Marlborough, Massachusetts and currently employs 6,990 full-time employees. The firm is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Diagnostics segment offers a wide range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Fluent fluid management system and Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment products include Horizon DXA Systems and Fluoroscan Insight FD.
HOLOGIC INC
250 Campus Drive
Marlborough MASSACHUSETTS 01752
P: 17819997300
CEO: STEPHEN P. MACMILLAN
Employees: 6990
Website: https://www.hologic.com/
Based on the average brokerage recommendation (ABR), Hologic (HOLX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Here is how High Tide Inc. (HITI) and Hologic (HOLX) have performed compared to their sector so far this year.
Review Hologic's (HOLX) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
HOLX stock results show that Hologic beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Here you can normally see the latest stock twits on HOLX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: